Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors

Abstract

Despite the progress made in the diagnoses and therapy of gastrointestinal cancers, these diseases are still plagued by a high mortality. Thus, novel therapeutic approaches are urgently required. In this regard, small interfering RNA (siRNA), double-stranded RNA molecules able to specifically target the mRNA of pathological genes, have the potential to be of therapeutic value. To be effective in the human body, siRNAs need to be protected against degradation. Additionally, they need to target the tumor, leaving the normal tissue untouched in an effort to preserve organ function. To accomplish these tasks, siRNAs have been formulated with smart delivery systems such has polymers and lipids. While siRNA protection is not particularly difficult to achieve, their targeting of tumor cells remains problematic. Here, after introducing the general features of gastrointestinal cancers, we describe siRNA characteristics together with representative delivery systems developed for gastrointestinal cancers. Afterward, we present a selection of research papers employing siRNAs against upper- and lower- gastrointestinal cancers. For the liver, we also consider papers using siRNAs to combat liver cirrhosis, a relevant risk factor for liver cancer development. Finally, we present a brief description of clinical trials employing siRNAs for gastrointestinal cancers.

Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches

“…A discussion of cancer-cell-targeted delivery approaches is not the focus of this review as it has been described elsewhere [18][19][20][21][22][23]. Here, instead, we emphasize on research studies dealing with the identification of biological molecules causing HCC.…”

Enhancing Effector Jurkat Cell Activity and Increasing Cytotoxicity against A549 Cells Using Nivolumab as an Anti-PD-1 Agent Loaded on Gelatin Nanoparticles

“…The interaction between PD-1 and its partner protein, PD-L1, is particularly noteworthy for its ability to prevent autoimmunity while also promoting immune evasion of tumor cells [ 4 , 5 ]. By exerting this inhibitory effect on T cells, PD-1/PD-L1 signaling helps maintain self-tolerance and prevent excessive inflammation or tissue damage resulting from an overactive immune response [ 6 ].…”

Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion

“…These types of tumors can affect several organs, such as the pancreas, liver, gallbladder, bile ducts, and colon. Because of the large cell mass and rapid turnover, GI cancers are among the most frequent neoplasms and are responsible for about half of all cancer-related deaths [ 1 ]. In fact, they account for 26% of global cancer incidence and 35% of all cancer-related deaths [ 2 ].…”